Formulated by 26 patents, the LifeAire technology specifically targets the cytotoxic levels of volatile organic compounds (VOCs), viable and nonviable particulates in air to bring levels within optimal ranges to protect the human embryo. Cells cultured in LifeAire-purified air have demonstrated statistically significant increases cellular metrics and clinical outcomes beyond any other technology in the market.